The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

Heparan sulfate proteoglycans (HSPG) are composed of unbranched, negatively charged
heparan sulfate (HS) polysaccharides attached to a variety of cell surface or extracellular …

Respiratory syncytial virus (RSV) infection is a significant cause of hospitalization of children
in North America and one of the leading causes of death of infants less than 1 year of age …

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in
young children and elderly people. Although the virus was isolated in 1955, an effective …

Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory disease in
infants, but no vaccine or effective therapy is available. The initiation of RSV infection of …

The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the
attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of …

RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has
limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding …

Human respiratory syncytial virus (RSV) causes a large burden of disease worldwide. There
is no effective vaccine or therapy, and the use of passive immunoprophylaxis with RSV …

Respiratory syncytial virus (RSV) is one of the most important viral pathogens causing
respiratory tract infection in infants, the elderly and people with poor immune function, which …

The airway epithelium provides a critical barrier to the outside environment. When its
integrity is impaired, epithelial cells and residing immune cells collaborate to exclude …